# Heron Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Heron Therapeutics, Inc). ## Overview Heron Therapeutics is a U.S.-based commercial-stage biotechnology company focused on acute care and oncology supportive care products. It develops and markets prescription therapies such as ZYNRELEF for postsurgical pain and injectable antiemetics used to prevent chemotherapy- and surgery-related nausea and vomiting. ## Products & services • ZYNRELEF extended-release postsurgical analgesia • APONVIE injectable emulsion for postoperative nausea/vomiting • CINVANTI injectable emulsion for chemotherapy-induced nausea/vomiting • SUSTOL extended-release injection for CINV prevention • U.S. commercial sales, distribution, and co-promotion support - **Acute care pain management** (33%) — Products used around surgery to reduce postoperative pain and opioid use, centered on ZYNRELEF. - **Oncology supportive care** (57%) — Injectable therapies used to prevent chemotherapy-induced nausea and vomiting, including CINVANTI and SUSTOL. - **Postoperative nausea and vomiting** (10%) — APONVIE and related antiemetic offerings used in surgical settings to prevent nausea and vomiting. - ZYNRELEF extended-release postsurgical analgesia - APONVIE injectable emulsion for postoperative nausea/vomiting - CINVANTI injectable emulsion for chemotherapy-induced nausea/vomiting - SUSTOL extended-release injection for CINV prevention - U.S. commercial sales, distribution, and co-promotion support ## Customers Heron sells primarily into the U.S. healthcare channel through specialty distributors and full-line wholesalers that resell to hospitals and healthcare providers. Its commercial team also targets surgeons, oncologists, nurses, pharmacists, managed care organizations, group purchasing organizations, hospital systems, oncology networks, payors, and government accounts because reimbursement and formulary access are critical to adoption. - **Specialty distributors and wholesalers** (primary) — Buy Heron's products in the U.S. and resell them to hospitals and providers; they are the direct commercial customers. - **Hospitals and ambulatory surgical settings** (primary) — Use ZYNRELEF and APONVIE in perioperative care to improve pain control and reduce nausea. - **Oncology clinics and infusion centers** (primary) — Use CINVANTI and SUSTOL to prevent chemotherapy-induced nausea and vomiting. - **Payors and managed care organizations** (secondary) — Influence coverage, reimbursement, and formulary access, which affect product uptake and net sales. - **Group purchasing organizations and hospital systems** (secondary) — Negotiate purchasing terms and access for institutional adoption across care networks. - Specialty distributors and full-line wholesalers buy product for resale - Hospitals and healthcare providers are the end users of the products - Surgeons and orthopedic specialists drive ZYNRELEF adoption - Oncologists, nurses, and pharmacists influence oncology product use - Payors and hospital systems matter because reimbursement and access determine uptake ## Geography Heron's business is overwhelmingly U.S.-centric, with commercial sales, sales and marketing, and customer relationships concentrated in the United States. The company notes that reimbursement and pricing are country-specific in foreign markets, but the disclosed commercial footprint and product sales described in the reports are primarily domestic. - U.S. is the core commercial market for all marketed products - Sales and marketing team is U.S.-based - Distribution runs through U.S. specialty distributors and wholesalers - Crosslink Network expands U.S. promotion for ZYNRELEF orthopedic use - Foreign market reimbursement is discussed as a potential future constraint ## Strategy Heron's strategy is to expand commercial adoption of its marketed products, especially ZYNRELEF, while maintaining a focused sales model in acute care and oncology. It is also using partnerships such as the Crosslink co-promotion agreement to broaden reach in orthopedic indications and improve product penetration without building a much larger internal field force. - **Grow ZYNRELEF adoption in orthopedic and surgical settings** (short-term) — ZYNRELEF is a key growth driver and label expansion broadens the addressable market. - **Improve commercial execution in acute care and oncology** (short-term) — The company depends on a small portfolio of marketed products, so execution directly affects revenue. - **Protect product access and reimbursement** (medium-term) — Coverage and reimbursement determine whether hospitals and payors adopt the products at scale. - Expand ZYNRELEF promotion in orthopedic indications - Use co-promotion partners to extend commercial reach efficiently - Support hospital and oncology access through reimbursement and account management - Maintain a focused U.S. sales force rather than broad direct selling - Defend and extend product life through label expansion and device improvements ## Risks Heron is highly dependent on a small number of commercial products, so any loss of market acceptance, reimbursement pressure, or competitive displacement could materially affect results. The company also faces supply-chain, manufacturing, regulatory, and commercialization risks that are common in specialty pharmaceuticals but especially important because it relies on third-party distribution and a limited product portfolio. - **Dependence on a limited product portfolio** [high] — The company's sales are concentrated in a few marketed products, so any weakness in one product can quickly affect total revenue. - **Reimbursement and pricing pressure** [high] — Hospitals, payors, and government programs must accept pricing and coverage for products to gain broad use. - **Supply chain and single-vendor dependence** [high] — The company disclosed that certain components may be sourced from a single vendor, creating disruption risk. - **Competition and generic entry** [medium] — Competing products can reduce market share, pressure pricing, and limit adoption of Heron's therapies. - **Regulatory and postmarketing obligations** [medium] — Label expansion, safety monitoring, and FDA requirements can affect commercialization timing and cost. - Revenue depends on a small number of marketed products - Reimbursement and pricing pressure can limit hospital adoption - Single-vendor or third-party supply disruptions could interrupt sales - Competition from branded and generic alternatives may erode share - Regulatory or postmarketing issues could restrict product use ## Accounting Heron's most important accounting judgments are revenue recognition for product sales, inventory and reserve estimates, and accrued clinical and manufacturing liabilities. Because product is sold through distributors and wholesalers with allowances and returns, reported revenue can be sensitive to estimates about sell-through, rebates, and other deductions; the company also notes seasonality and commercialization timing can affect comparability. - **Revenue recognition and sales allowances** — Net sales for ZYNRELEF, APONVIE, CINVANTI, and SUSTOL - **Inventory reserves and manufacturing liabilities** — Cost of product sales and gross margin - **Accrued clinical and manufacturing liabilities** — Operating expenses and liabilities - **Stock-based compensation** — Operating expense and dilution - Product revenue is recognized when control transfers, usually on delivery - Sales allowances and reserves affect net product sales - Inventory and manufacturing reserves can move with demand and supply issues - Accrued clinical and manufacturing liabilities depend on estimates - Stock-based compensation and debt/equity transactions affect reported expenses --- *Last updated: 2026-09-24T12:25:46.086779+00:00*